Immunization with cross-conserved H1N1 influenza CD4⁺ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice

References

• Perrone LA, Ahmad A, Veguilla V, Lu X, Smith G, Katz JM, Pushko P, Tumpey TM. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol 2009; 83:5726 - 34; http://dx.doi.org/10.1128/JVI.00207-09; PMID: 19321609
   PubMed Web of Science ®Google Scholar
• Ellebedy AH, Fabrizio TP, Kayali G, Oguin TH 3rd, Brown SA, Rehg J, Thomas PG, Webby RJ. Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) Virus vaccination in ferrets. Clin Vaccine Immunol 2010; 17:1998 - 2006; http://dx.doi.org/10.1128/CVI.00247-10; PMID: 20962210
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008; 3:e1501; http://dx.doi.org/10.1371/journal.pone.0001501; PMID: 18231588
   PubMed Web of Science ®Google Scholar
• Laurie KL, Carolan LA, Middleton D, Lowther S, Kelso A, Barr IG. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis 2010; 202:1011 - 20; http://dx.doi.org/10.1086/656188; PMID: 20715930
   PubMed Web of Science ®Google Scholar
• Pearce DC, Pallaghy PK, McCaw JM, McVernon J, Mathews JD. Understanding mortality in the 1918-1919 influenza pandemic in England and Wales. Influenza Other Respi Viruses 2011; 5:89 - 98; http://dx.doi.org/10.1111/j.1750-2659.2010.00186.x; PMID: 21306572
   PubMed Web of Science ®Google Scholar
• Gaydos JC, Top FH Jr., Hodder RA, Russell PK. Swine influenza a outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis 2006; 12:23 - 8; http://dx.doi.org/10.3201/eid1201.050965; PMID: 16494712
   PubMed Web of Science ®Google Scholar
• Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009; 106:20365 - 70; http://dx.doi.org/10.1073/pnas.0911580106; PMID: 19918065
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia L, Valdespino-Gómez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, Cruz-Hervert P, Cano-Arellano B, Garcia-Anaya A, Ferreira-Guerrero E, Baez-Saldaña R, et al. Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 2009; 339:b3928; http://dx.doi.org/10.1136/bmj.b3928; PMID: 19808768
   PubMedGoogle Scholar
• De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 2009; 27:5740 - 7; http://dx.doi.org/10.1016/j.vaccine.2009.07.040; PMID: 19660593
   PubMed Web of Science ®Google Scholar
• Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197 - 201; http://dx.doi.org/10.1126/science.1176225; PMID: 19465683
   PubMed Web of Science ®Google Scholar
• Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS. Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. [Epub ahead of print] Hum Vaccin Immunother 2013; 9; http://dx.doi.org/10.4161/hv.25598; PMID: 23846304
   PubMed Web of Science ®Google Scholar
• Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, Jung G, Rammensee HG. Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990; 348:252 - 4; http://dx.doi.org/10.1038/348252a0; PMID: 1700304
   PubMed Web of Science ®Google Scholar
• Kong YC, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G, Hämmerling GJ, David CS. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med 1996; 184:1167 - 72; http://dx.doi.org/10.1084/jem.184.3.1167; PMID: 9064334
   PubMed Web of Science ®Google Scholar
• Co MD, Orphin L, Cruz J, Pazoles P, Green KM, Potts J, Leporati AM, Babon JA, Evans JE, Ennis FA, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 2009; 27:319 - 27; http://dx.doi.org/10.1016/j.vaccine.2008.09.092; PMID: 18977404
   PubMed Web of Science ®Google Scholar
• Lee LY, Ha LA, Simmons C, de Jong MD, Chau NV, Schumacher R, Peng YC, McMichael AJ, Farrar JJ, Smith GL, et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 2008; 118:3478 - 90; PMID: 18802496
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Bennink JR, Smith GL, Moss B. Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1985; 82:1785 - 9; http://dx.doi.org/10.1073/pnas.82.6.1785; PMID: 3872457
   PubMed Web of Science ®Google Scholar
• Epstein SL, Lo CY, Misplon JA, Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998; 160:322 - 7; PMID: 9551987
   PubMed Web of Science ®Google Scholar
• Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 2009; 27:6512 - 21; http://dx.doi.org/10.1016/j.vaccine.2009.08.053; PMID: 19729082
   PubMed Web of Science ®Google Scholar
• Alexander J, Bilsel P, del Guercio MF, Stewart S, Marinkovic-Petrovic A, Southwood S, Crimi C, Vang L, Walker L, Ishioka G, et al. Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice. Vaccine 2010; 28:664 - 72; http://dx.doi.org/10.1016/j.vaccine.2009.10.103; PMID: 19895924
   PubMed Web of Science ®Google Scholar
• Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol 2010; 185:4998 - 5002; http://dx.doi.org/10.4049/jimmunol.1001395; PMID: 20889549
   PubMed Web of Science ®Google Scholar
• Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Qin G, Chan PL, Lam KT, Guan J, Zhang L, et al. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol 2010; 84:6527 - 35; http://dx.doi.org/10.1128/JVI.00519-10; PMID: 20410263
   PubMed Web of Science ®Google Scholar
• Ge X, Tan V, Bollyky PL, Standifer NE, James EA, Kwok WW. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol 2010; 84:3312 - 9; http://dx.doi.org/10.1128/JVI.02226-09; PMID: 20071564
   PubMed Web of Science ®Google Scholar
• Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, Rubrum AM, Govorkova EA, Webster RG, Webby RJ. Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine 2011; 29:3335 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.08.067; PMID: 20840835
   PubMed Web of Science ®Google Scholar
• Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013;; pii:S1879 - 6257; PMID: 23978327
   PubMedGoogle Scholar
• Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:e3942; http://dx.doi.org/10.1371/journal.pone.0003942; PMID: 19079604
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011; 333:850 - 6; http://dx.doi.org/10.1126/science.1205669; PMID: 21798894
   PubMed Web of Science ®Google Scholar
• Schanen BC, De Groot AS, Moise L, Ardito M, McClaine E, Martin W, Wittman V, Warren WL, Drake DR 3rd. Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine 2011; 29:3299 - 309; http://dx.doi.org/10.1016/j.vaccine.2011.02.019; PMID: 21349362
   PubMed Web of Science ®Google Scholar
• Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, Baxter-Lowe LA. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006; 203:961 - 71; http://dx.doi.org/10.1084/jem.20052471; PMID: 16585267
   PubMed Web of Science ®Google Scholar
• Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363 - 73; PMID: 9531296
   PubMed Web of Science ®Google Scholar
• De Groot AS, Marcon L, Bishop EA, Rivera D, Kutzler M, Weiner DB, Martin W. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005; 23:2136 - 48; http://dx.doi.org/10.1016/j.vaccine.2005.01.097; PMID: 15755584
   PubMed Web of Science ®Google Scholar
• FDA Center for Biologics Evaluation and Research (CBER). Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Diseases Indications. (Docket no. 96N-0400).
   Google Scholar
• Reed LJ, Muench HA. A simple method of estimating fifty percent endpoints. Am J Hyg 1938; 27:493 - 7
   Google Scholar